In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell ...

ES-SCLC is a form of lung cancer accounting for one in eight lung cancer cases in the UK. It is an aggressive disease that progresses rapidly, with a significant negative impact on the quality of ...

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...

Roche pointed out that ES-SCLC is challenging, and Tecentriq plus chemo remains the standard of care for patients, but the setbacks is a blow to its attempts to show that two immunotherapies can ...

as a first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC). “The aggressive nature of extensive-stage small cell lung cancer makes it an extremely ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for ...